February 7, 2007 -- Chinese biotech 3SBio priced its IPO at $16, well above the proposed $12-$14 range, though it did not fare as well in open-market trading; Accuray raised its proposed IPO range to $17-$18, a 17% increase; Biogen Idec began a registration trial for leukemia drug lumiliximab; ViroPharma was given Orphan Drug designation for maribavir to prevent cytomegalovirus; Bioenvision asked European authorities to extend the indication for Evoltra to include acute myeloid leukemia (AML) patients who are older than 65; and Forest Labs ended its year-old partnership with Replidyne, which was developing the antibiotic faropenem. The Centient Biotech 200™ rose 15 points to 4065, a gain of .36%. More details...
